Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VIO 01

Drug Profile

VIO 01

Alternative Names: OX-425; VIO-01

Latest Information Update: 03 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Onxeo SA
  • Developer Valerio Therapeutics
  • Class Antineoplastics; Immunotherapies; Oligonucleotides
  • Mechanism of Action Ku autoantigen modulators; MRE11 homologue protein modulators; MutS homolog 2 protein modulators; Poly(ADP-ribose) polymerase-1 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 26 Feb 2024 Pharmacodynamics, adverse events and pharmacokinetics data from a preclinical trial in Cancer presented at the ESMO Targeted Anticancer Therapies Congress 2024 (ESMO-2024)
  • 10 Jan 2024 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Combination therapy, Second-line therapy or greater, Metastatic disease) in USA (IV-infusion) (NCT06257758)
  • 10 Jan 2024 Phase-I/II clinical trials in Solid tumours (Monotherapy, Second-line therapy or greater, Metastatic disease, Late-stage disease) in USA (IV-infusion) (NCT06257758)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top